Stenotrophomonas maltophilia
Stenotrophomonas maltophilia is a Gram-negative, aerobic, non-fermentative, non-spore-forming, motile, bacterial species. It is found in various aquatic environments, and is also an opportunistic pathogen, particularly in hospital environments.
Characteristics[edit]
Stenotrophomonas maltophilia is characterized by its multidrug resistance, which makes it a significant pathogen in healthcare settings. It is resistant to many broad-spectrum antibiotics, including carbapenems and aminoglycosides, but is typically sensitive to trimethoprim/sulfamethoxazole (TMP/SMX).
Pathogenicity[edit]
Stenotrophomonas maltophilia is an opportunistic pathogen, meaning it primarily affects individuals with weakened immune systems. It can cause a variety of infections, including pneumonia, bloodstream infections, skin infections, and eye infections. Infections are often associated with significant morbidity and mortality.
Treatment[edit]
Treatment of Stenotrophomonas maltophilia infections can be challenging due to the organism's inherent multidrug resistance. The antibiotic trimethoprim/sulfamethoxazole (TMP/SMX) is typically the first-line treatment. In cases where the patient is allergic to or cannot tolerate TMP/SMX, other options include ceftazidime, levofloxacin, and minocycline.
Epidemiology[edit]
Stenotrophomonas maltophilia is found worldwide in various aquatic environments, including water, soil, and plants. It is also commonly found in hospital environments, particularly on surfaces and in medical devices such as catheters and ventilators.
See also[edit]
-
Stenotrophomonas maltophilia
-
Stenotrophomonas maltophilia
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian